{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"condition":["Colorectal Cancer","Colorectal Neoplasms","Colorectal cancer (CRC)","Metastatic colorectal cancer"],"disease":["Metastatic Colorectal Cancer","Colorectal Cancer (crc)","Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2275230"],"location":["South Korea","United States","United Kingdom","Australia","France","Switzerland","Spain"],"study_start_month":["9"],"keyword":["IMPRIME PGG","Selicrelumab","ISATUXIMAB","REGORAFERIB","Idasanutlin","Atezolizumab","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)","description":"A phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with metastatic colorectal cancer (mCRC) that became refractory to first- and second-line standard therapies. Eligible patients will be assigned to one of several treatment arms.","dates":{"creation":"2018-09-15"},"accession":"2275230","cross_references":{"ClinicalTrials___gov":["NCT03555149"],"EU Clinical Trials Register":["2017-004566-99"]}}